Last reviewed · How we verify
NCT05159544
The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population
trial in Cancer in 60,000 participants. Currently enrolling.
6 July 2024
Quick facts
| Lead sponsor | Singlera Genomics Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60,000 |
| Start date | 6 July 2021 |
| Primary completion | 6 July 2024 |
| Estimated completion | 7 December 2024 |
| Sites | 12 locations across China |
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
Singlera Genomics Inc.
Who can join
Adults 40 to 75, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The integrative study by Fudan and Singlera for cancer early detection(The FuSion Program ) will evaluate sensitivity,specificity and positive/negative predictive value of the screening model jointly developed by FuDan University and Singlera in a 2-year follow-up corhort including 10,000 persons in routine annual physicals from dozens of hospitals. The multi-omics model for pan-cancer screening will be developed in a 3-year follow-up corhort including 50,000 natural persons in community containing genetic information of tumor families, assessment of epidemiological risk factors, tumor markers, proteomics, genomics and DNA methylation. After optimizing, the ability of this model will be validated in the Taizhou corhort in reality.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. · · 2023 · cited 72× · PMID 36980276 · DOI 10.3390/cells12060935 -
Screening for pancreatic cancer has the potential to save lives, but is it practical?
Mazer BL, Lee JW, Roberts NJ, Chu LC, et al · · 2023 · cited 23× · PMID 37212770 · DOI 10.1080/17474124.2023.2217354 -
Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Imai M, Nakamura Y, Yoshino T. · · 2025 · cited 15× · PMID 39799530 · DOI 10.1007/s10147-025-02694-5 -
Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.
Galeș LN, Păun MA, Anghel RM, Trifănescu OG. · · 2024 · cited 9× · PMID 38539525 · DOI 10.3390/cancers16061191 -
Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.
Xu Y, Zhu S, Xia C, Yu H, et al · · 2025 · cited 2× · PMID 40670203 · DOI 10.1016/j.scib.2025.06.030
Verify or expand the search:
- PubMed search for NCT05159544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Singlera Genomics Inc. trials
Trials by the same sponsor.
- NCT06842563 — Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinica · active not recruiting
- NCT06440018 — INSPIRE: a Multi-Cancer Early Detection Study · recruiting
- NCT06895551 — Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection · completed
- NCT05485077 — A Prospective Cohort Study on Colorectal Cancer Screening in Community Population · recruiting
- NCT05444491 — Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05159544 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Singlera Genomics Inc.
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05159544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing